Landscapes / Companies
Ionis Pharmaceuticals, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
4 approved
2 in Phase 3
Drugs
13
in active trials · 39 in all
Trials
19 active
76 since 2021
Drugs13
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Hereditary Angioedema, Hereditary Angioedema (HAE) | ||||
| Open drug page | |||||
APOC-III-directed RNA Interaction; antisense oligonucleotide |
Approved | Mar 2027Phase 3 trial completes | |||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia | ||||
| Open drug page | |||||
Transthyretin-directed RNA Interaction; antisense oligonucleotide |
AstraZeneca |
Approved | 6 Feb 2029Phase 2 trial completes | ||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | 6 Feb 2029 · Phase 2 trial completes | ||||
| Also tested for | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) and 2 more | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Alexander Disease | ||||
| Open drug page | |||||
— |
Phase 3 | Aug 2027Phase 3 trial completes | |||
| Next date | Aug 2027 · Phase 3 trial completes | ||||
| Also tested for | Angelman Syndrome | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Amyotrophic Lateral Sclerosis | ||||
| Open drug page | |||||
— |
Kardigan |
Phase 2 | Dec 2026Phase 2 trial completes | ||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Hypertension, Acute Severe Hypertension and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Prion Disease | ||||
| Open drug page | |||||
— |
Phase 1/2 | Sep 2027Phase 1/2 trial completes | |||
| Next date | Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | ||||
| Open drug page | |||||
— |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Hypertriglyceridemia, Severe Hypertriglyceridemia | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2030Phase 1/2 trial completes | |||
| Next date | Dec 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Dravet Syndrome | ||||
| Open drug page | |||||
— |
Phase 1 | Sep 2027Phase 1 trial completes | |||
| Next date | Sep 2027 · Phase 1 trial completes | ||||
| Also tested for | Multiple System Atrophy | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2028Phase 1 trial completes | |||
| Next date | Jun 2028 · Phase 1 trial completes | ||||
| Also tested for | Pelizaeus-Merzbacher Disease | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 26 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021